Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRL_AB vs Orencia IV in rheumatoid arthritis
2023-506664-14-00Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of DRL_AB in rheumatoid arthritis (RA) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Change in DAS28-CRP from baseline to Week 13. Started Apr 2024; status: completed.
02
Drugs
DRL_AB
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-506664-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506664-14-00.